Effect of telmisartan in hypertensive patients with impaired fasting glycaemia
Keywords:Hypertension, Impaired fasting glycaemia, PPAR gamma, Telmisartan
Background: Telmisartan, an angiotensin II receptor blocker, has a higher affinity for AT1 receptors. It has also been recognized as partial agonist of the nuclear hormone receptor PPAR-gamma. The present study is conducted to study the effect of Telmisartan in hypertensive patients with impaired fasting glycaemia.
Methods: This is a prospective and randomised study done on 50 hypertensive patients with impaired fasting glycaemia. All the patients underwent following investigations like Fasting plasma glucose, blood pressure and body mass index were also measured.
Results: Fasting plasma glucose, blood pressure (SBP, DBP) showed significant decrease after intake of 40 mg Telmisartan for three months. Changes in BMI are not significant.
Conclusions: The present study shows that Telmisartan is effective in controlling blood-pressure by its AT1 receptor blocking activity. It is also effective in decreasing fasting blood glucose by its insulin sensitizing activity through partial peroxisome proliferator activated receptor (PPAR) gamma activity.
Akintunde AA, Epidemilogy of conventional cardiovascular risk factor among hypertensive subjects with normal and impaired fasting glucose. SAMJ. 2010;100(9):594.
Yusuf S, Reddy S, Dompao S. Global burden of cardiovascular disease Part I. General considerations, the epidemiologic transition, risk factor and impact of urbanization. Circulat. 2001;104:2746-53.
Whitworth JA. 2003 WHO/International Society of Hypertension (ISH) Statement on management of hypertension. J Hypert. 2003,21:1983-1992.
Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes risk calculator. Diab Care. 20081;31(5):1040-5.
Watanabe M. Effect of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med. 2010;49:1843-7.
Vitale C, Mercuro G, Castiglioni C, Cornoldi A, Tulli A, Fini M, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology. 2005;15;4(1):6.
Wofford MR, King DS. Deborah SK. Relationship between antihypertensive drugs and metabolic syndrome. Metab Syndr Relat Disord. 2004;2(4):308-14.
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diab Care. 1997;20:7:1183-97.
Unger T. Preclinical and clinical effects of RAS inhibition with a focus on telmisartan. ISRN Vascular Medicine. 2012;2012.
Kurtz TW. Anti-diabetic mechanism of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists: beyond the rennin-angiotensin system. J Hypert. 2004;22(12)2253-61.
Henry P. Impaired fasting glucose, blood pressure and cardiovascular disease mortality. Hypert. 2002;40:458-63.
Bähr IN, Tretter P, Krüger J, Stark RG, Schimkus J, Unger T et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome. Hypert. 2011;58(4):725-32.